CN112516126A

CN112516126A - New application of pravastatin

Info

Publication number: CN112516126A
Application number: CN202011309822.XA
Authority: CN
Inventors: 刘克玄; 邓凡; 胡敬娟
Original assignee: Southern Hospital Southern Medical University
Current assignee: Southern Hospital Southern Medical University
Priority date: 2020-11-20
Filing date: 2020-11-20
Publication date: 2021-03-19

Abstract

The invention relates to a new application of pravastatin, in particular to an application of pravastatin in preparing a medicine for preventing or/and treating intestinal ischemia-reperfusion injury. Compared with the prior art, the invention has the following beneficial effects: the invention uses pravastatin for preventing and/or treating intestinal ischemia-reperfusion injury, and the effect of the drug is verified on the constructed classical intestinal ischemia-reperfusion model, and the verification result shows that the pravastatin obviously improves the intestinal tissue injury induced by the intestinal ischemia-reperfusion of mice, improves the survival rate of the mice, inhibits the expression of inflammatory factors, has obvious effect, is safe and nontoxic, and has small side effect.

Description

New application of pravastatin

Technical Field

The invention relates to the technical field of medicines, in particular to a new application of pravastatin, and specifically relates to an application of pravastatin in preparation of medicines for preventing or/and treating intestinal ischemia-reperfusion injury.

Background

Pravastatin (PA) is one of the statins, a lipid regulating drug used to reduce cholesterol and prevent cardiovascular diseases. Pravastatin is a competitive inhibitor of 3-hydroxy 3-methylglutaryl coenzyme A reductase and inhibits the biosynthesis of cholesterol. Pravastatin having the molecular formula C₂₃H₃₆NaO₇Molecular weight 447.5, chemical bondThe structure is as follows:

pravastatin has effects of inhibiting inflammatory reaction, improving oxidative stress, and reducing platelet activity.

Intestinal ischemia reperfusion (I/R) injury is common pathological change in surgery, is a phenomenon of blood flow reperfusion aggravated injury after ischemia of intestinal tissue organs, is common in perioperative period, and plays an important role in the occurrence and development of fatal diseases such as severe infection and traumatic shock. Intestinal ischemia reperfusion not only can cause local damage to intestinal tracts, but also causes bacterial translocation of intestinal tracts, endotoxin outward migration due to the damage of intestinal mucosal barriers, and various locally generated free radicals enter blood and are displaced to tissue organs outside the intestines, thereby causing the function insufficiency, even failure and death of multiple organs outside the intestines.

The ischemia reperfusion injury of the intestine has high morbidity and mortality in the clinical perioperative period. However, no effective drug for treating ischemia-reperfusion injury of the intestine has been developed. Therefore, exploring an effective prevention and treatment strategy for the intestinal ischemia-reperfusion injury is a technical problem to be solved clinically at present.

Disclosure of Invention

Based on the above, the invention provides a new application of pravastatin, and particularly relates to an application of pravastatin in preparation of a medicine for preventing or/and treating intestinal ischemia-reperfusion injury.

The technical scheme of the invention is as follows:

application of pravastatin in preparing a medicament for preventing or/and treating intestinal ischemia-reperfusion injury.

In one embodiment, the medicament comprises pravastatin and pharmaceutically acceptable auxiliary materials.

In one embodiment, 1.5mg to 2.5mg of said pravastatin is contained per 1kg of said drug.

In one embodiment, the dosage form of the drug is a tablet.

In one embodiment, the tablet is a coated tablet.

In one embodiment, the dosage form of the medicament is a capsule.

In one embodiment, the dosage form of the medicament is an oral liquid.

In one embodiment, the dosage form of the medicament is oral granules.

In one embodiment, the dosage form of the medicament is an oral powder.

In one embodiment, the pharmaceutical formulation is an injection.

In one embodiment, the injection is a lyophilized powder injection.

In one embodiment, the injection is an emulsion for injection.

Compared with the prior art, the invention has the following beneficial effects:

the invention uses pravastatin for preventing and/or treating intestinal ischemia-reperfusion injury, and the effect of the drug is verified on the constructed classical intestinal ischemia-reperfusion model, and the verification result shows that the pravastatin obviously improves the intestinal tissue injury induced by the intestinal ischemia-reperfusion of mice, improves the survival rate of the mice, inhibits the expression of inflammatory factors, has obvious effect, is safe and nontoxic, and has small side effect.

Drawings

FIG. 1 is a graph of the results of pravastatin increasing survival of mice with intestinal ischemia reperfusion; wherein, the meaning of the reference symbols in fig. 1 is: the data are in Log-rank (Mantel-Cox) test, representing that the difference compared with the I/R group has statistical significance p < 0.05;

FIG. 2 is a graphical representation of the pathological consequences of pravastatin on the improvement of intestinal ischemia-reperfusion-induced intestinal tissue damage in mice; wherein, FIG. 2A is HE staining diagram of morphological change of intestinal tissues of each group, FIG. 2B is quantitative scoring result of intestinal tissue damage of each group, and the picture scale is 100 μm; the notations in the figures mean: data were analyzed using a one-way ANOVA test, indicating that the differences compared to the I/R group had a statistical significance p < 0.05;

FIG. 3 is a bar graph of the level of mRNA expression of intestinal tissue inflammatory factor induced by reduction of intestinal ischemia-reperfusion in mice by pravastatin; wherein, the meaning of the reference symbols in the figures is: data were analyzed using a one-way ANOVA test, indicating that the differences compared to the I/R group had a statistical significance p < 0.05.

Detailed Description

In order that the invention may be more fully understood, reference will now be made to the following description. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.

Experimental procedures without specific conditions noted in the following examples, generally followed by conventional conditions, such as Sambrook et al, molecular cloning: the conditions described in the Laboratory Manual (New York: Cold Spring Harbor Laboratory Press,1989), or according to the manufacturer's recommendations. The various chemicals used in the examples are commercially available.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.

To facilitate an understanding of the present application, some terms and expressions in the text of the present invention shall be explained below.

As used herein, the term "ischemia" relates to a condition that may occur in any organ or tissue that lacks a supply of oxygen and/or a supply of metabolites. Ischemia occurs when there is an imbalance between the supply and demand for oxygen due to insufficient perfusion (i.e., blood supply). Insufficient oxygen supply may be caused by thrombosis, the presence of stenotic atherosclerosis, restenosis, anemia, stroke, arterial clotting, vasoconstriction and/or endothelial dysfunction of the microvasculature (taco-scotch syndrome).

The term "ischemia reperfusion injury," refers to organ or tissue damage due to insufficient blood supply to the organ or tissue during ischemia prior to the onset of reperfusion (i.e., an ischemia injury is an injury caused by ischemia during the time between the onset of ischemia and the onset of reperfusion).

The typical and pathological manifestation of ischemic injury is the pale ischemic area. In contrast, in reperfusion, non-necrotic ischemic tissue regains its physiological color.

From a biochemical point of view, ischemic injury is characterized by local pH (acidification) changes in ischemic tissue and systemic in blood (leukocytes, preferably PBMCs), ATP concentration changes, increased susceptibility of platelets to activation, enhanced inflammatory responses in both ischemic tissue and the blood system.

Ischemic injury may be caused, for example, by atherosclerosis, thrombosis, thromboembolism, lipid embolism, hemorrhage, stenting, surgery, angioplasty, intra-operative bypass bridging, organ transplantation, total ischemia, myocardial infarction, vasoconstriction, microvascular dysfunction, and/or combinations of two or more thereof.

Ischemic injury may involve cell death of muscle cells (preferably by necrosis and/or apoptosis, more preferably by necrosis), injury due to acidification of intracellular pH by ischemia, and/or injury due to an inflammatory response initiated by ischemia and further amplified during reperfusion.

During ischemia, anaerobic metabolism predominates, resulting in a decrease in cell pH. To buffer this accumulation of hydrogen ions, Na⁺/H⁺The exchanger discharges excess hydrogen ions, which creates a large influx of sodium ions. Carlo Geris (Kalogeris) et al, Int Rev Cell Mol biol.2012; 298: 229-. Ischemia also depletes cellular ATP, inactivates ATPases (e.g., Na +/K + ATPase), and reduces active Ca²⁺Efflux and restriction of calcium reuptake by the Endoplasmic Reticulum (ER) resulting in intracellular calcium overload. These changes are accompanied by Mitochondrial Permeability Transition (MPT) poresOpen, the opening of the MPT pore dissipates mitochondrial membrane potential and further attenuates ATP production. These changes, and therefore the degree of tissue damage, vary somewhat with the magnitude of the diminished blood supply and the duration of the ischemic period.

Ischemic injury may involve the following symptoms: chest discomfort, shortness of breath, discomfort in other areas of the upper body, feeling nausea and/or anxiety.

As used herein, the term "reperfusion" relates to the restoration of blood flow to an ischemic tissue. Despite the clear benefits of blood reperfusion to ischemic tissues, it is well known that reperfusion itself can lead to a series of paradoxically adverse effects that damage tissues.

As used herein, the term "reperfusion injury" relates to organ or tissue damage caused when blood supply is returned to the organ or tissue after an ischemic period. Thus, a reperfusion injury is an injury caused during the time between the beginning of reperfusion and the end of reperfusion (typically, a major portion of the injury will be caused within the first few minutes of reperfusion). The underlying mechanisms of reperfusion injury are complex, multifactorial, and involve (1) reintroduction of molecular oxygen at the time of reestablishment of blood flow to promote the production of Reactive Oxygen Species (ROS), (2) calcium overload, (3) opening of MPT pores, (4) endothelial dysfunction, (5) appearance of a prothrombotic phenotype, and (6) a significant inflammatory response. The lack of oxygen and nutrients in the blood during the ischemic period creates a situation in which restoration of circulation leads to inflammation and oxidative damage by inducing oxidative stress rather than restoring normal function. Oxidative stress associated with reperfusion can cause damage to the affected tissue or organ. The biochemistry of reperfusion injury is characterized by oxygen depletion during an ischemic event, followed by reoxygenation during reperfusion and concomitant production of reactive oxygen species. The damage that occurs with reperfusion is the result of interaction between the substances accumulated during ischemia and the substances delivered upon reperfusion. The basis of these events is oxidative stress, which is defined as an imbalance between oxygen free radicals and endogenous clearance systems. The result is cell damage and death, which is initially local but eventually becomes systemic if the inflammatory response is not examined.

Reperfusion injury is primarily characterized by oxygen burst and inflammatory response reperfusion injury and consequent tissue damage that may occur following revascularization of infarcted (ischemic) tissue. This is associated with an impairment of mitochondrial membrane potential, further with progression of apoptosis, reperfusion-related arrhythmias, cardiac arrest and an overall increase in infarct size caused by ischemia. Thus, the final infarct size (tissue damage) depends on the ischemic damage (tissue damage caused by itself during ischemia) and to a lesser extent on the tissue damage caused by reperfusion.

Reperfusion injury may be caused, for example, by a mechanical event, or by one or more surgical procedures or other therapeutic intervention to restore blood flow to a tissue or organ that has experienced a reduced blood flow supply. Such surgical procedures include, for example, coronary artery bypass graft surgery, coronary angioplasty, and organ transplant surgery, among others. In particular embodiments, the reperfusion injury results from treatment of an ischemic process resulting from rupture/erosion of atherosclerotic plaques and superimposition of thrombus, thromboembolism, lipid embolism, hemorrhage, stent, surgery, angioplasty, end of shunt during surgery, organ transplantation, total ischemia, vasoconstriction or microvascular dysfunction or a combination thereof.

Reperfusion injury may involve oxidative damage, and damage and/or myocardial cell death due to an inflammatory response that, although weak, is initiated during ischemia but becomes evident upon reperfusion. Preferably, reperfusion injury involves oxidative damage, damage due to inflammatory reactions and cardiomyocyte death. More preferably, reperfusion injury involves oxidative damage, damage due to inflammatory response and myocardial cell death, rather than acidification due to intracellular pH.

Reperfusion injury may involve symptoms of palpitations, acute respiratory distress, fatigue, and/or edema.

The embodiment of the invention relates to the following:

the embodiment of the invention relates to application of pravastatin in preparing a medicament for preventing or/and treating intestinal ischemia-reperfusion injury.

Preferably, the medicament comprises pravastatin and pharmaceutically acceptable auxiliary materials.

Preferably, 1.5mg to 2.5mg of said pravastatin is contained per 1kg of said drug.

It is understood that the drugs of the embodiments of the present invention can be prepared into suitable clinical dosage forms by adding various pharmaceutically acceptable excipients, including but not limited to the following dosage forms: tablets (including but not limited to coated tablets), capsules, oral liquid, oral granules, oral powder and injection (including but not limited to freeze-dried powder injection or emulsion for injection). Such pharmaceutically acceptable excipients include, but are not limited to, diluents, wetting agents, binders, disintegrants, lubricants, color, flavor modifiers, solvents, solubilizers, emulsifiers, antioxidants, metal complexing agents, inert gases, preservatives, topical analgesics, pH modifiers, isotonic or isotonic adjusting agents, and the like. Further: diluents such as starch, sucrose, celluloses, inorganic salts, etc.; wetting agents such as water, ethanol, and the like; adhesives such as starch slurry, dextrin, sugar, cellulose derivatives, gelatin, povidone, polyethylene glycol, and the like; disintegrants, such as starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, sodium croscarmellose, crospovidone, surfactants, transpiration disintegrants, and the like; lubricants such as talc, calcium stearate, magnesium lauryl sulfate, colloidal silica, polyethylene glycol, and the like; color, flavor and taste modifiers such as pigment, perfume, sweetener, mucilage, and flavoring agent, specifically fuchsin and xylitol; solvents such as water, oil, ethanol, glycerin, propylene glycol, polyethylene glycol, dimethyl sulfoxide, liquid paraffin, fatty oil, ethyl acetate, etc.; solubilizers such as tweens, maizes, polyoxyethylene fatty alcohol ethers, soaps, sulfates, sulfonates, and the like; cosolvents such as organic acids (e.g., citric acid) and salts thereof, amides and amines, inorganic salts, polyethylene glycol, povidone, glycerol, and the like; emulsifying agents, such as span, tween, maize, benze, glycerin fatty acid ester, higher fatty acid salt, sulfate, sulfonate, gum arabic, tragacanth, gelatin, pectin, phospholipid, agar, sodium alginate, hydroxide, silica, bentonite, etc.; suspending agents such as glycerol, syrup, acacia, tragacanth, agar, sodium alginate, cellulose derivatives, povidone, carbopol, polyvinyl alcohol, thixotrope, etc.; antioxidants such as sulfites, pyrosulfites, bisulfites, ascorbic acid, gallic acid and esters thereof, and the like; metal complexing agents such as disodium ethylenediaminetetraacetate, polycarboxylic acid compounds, and the like; inert gases such as nitrogen, carbon dioxide, and the like; preservatives, such as parabens, organic acids and salts thereof (e.g., sodium benzoate), quaternary ammonium compounds, chlorhexidine acetate, alcohols, phenols, volatile oils, and the like; local analgesics such as benzyl alcohol, chlorobutanol, lidocaine, procaine and the like; pH regulators such as hydrochloric acid, sulfuric acid, phosphoric acid, tartaric acid, acetic acid, sodium hydroxide, sodium bicarbonate, ethylenediamine, meglumine, phosphate, acetate, citric acid, citrate, etc.; isotonic or isotonic regulator, such as glucose, sodium chloride, sodium citrate, sorbitol, xylitol, etc. It is understood that the diluents of the embodiments of the present invention may also be called bulking agents, and may function in the same manner in pharmaceutical formulations; the water in the embodiment of the invention is water meeting the requirements of medicaments, such as water for injection, purified water and the like, and the oil is oil for injection; the preservative provided by the embodiment of the invention can also be called as an antibacterial agent, and plays roles of inhibiting the growth of microorganisms, prolonging the shelf life and the like in a preparation; the lubricant of the embodiment of the invention contains glidant, anti-adhesive agent and the like; the sugar in the embodiment of the invention can be sugar powder or syrup, and the type of the sugar is not limited to glucose; the perfume described in the embodiment of the present invention includes, but is not limited to, essence.

It is understood that the drugs according to the embodiments of the present invention are based on different excipients and prepared into different dosage forms, and accordingly, the administration mode may be varied.

Example 1: pravastatin can improve the survival rate of mice intestinal ischemia reperfusion injury

1 materials of the experiment

1.1 Experimental animals

60 male C57BL/6J mice with the age of 6-8 weeks are selected for experiments, the weight of the mice is 18-22 g, the mice are purchased from the center of animals in southern hospitals, the breeding place is the SPF animal laboratory department of southern hospitals of southern medical university, and the operations involved in the animal breeding process are approved by the ethical committee and meet the ethical requirements of animals.

1.2 reagents and instruments

Pravastatin (MedChemExpress, USA); isoflurane (rewarded life science co.); microvascular arterial clamps (gooey biotechnology limited, chengdu north america); sterile silk thread (Ningbo medical suture needle Co., Ltd.); physiological saline (Shijiazhuang four drugs Co., Ltd.); phosphate Buffer Saline (PBS) pH7.4 buffer (Gibco).

2 experimental methods and results

2.1 animal experiments

(1) Establishing an I/R model of the mouse superior mesenteric artery (the intestinal ischemia reperfusion animal model is a perioperative intestinal injury model constructed by classical superior mesenteric artery clamp):

fasting for 12h before operation, freely drinking water, inhaling isoflurane into the anesthetized mice, and clamping the superior mesenteric artery with a non-invasive microvascular artery clamp to block blood flow.

After intestinal ischemia lasts for 60min, loosening the artery clamp to recover blood supply, performing intestinal reperfusion, and suturing peritoneum, muscle and skin layer by layer with sterile silk thread after checking no bleeding in the abdominal cavity.

After the block and when the reperfusion, 0.5ml of warm physiological saline at about 37 ℃ is injected subcutaneously for liquid recovery, and the survival perfusion time of the mice is observed and recorded.

(2) Grouping experiments:

24C 57BL/6 mice were randomly divided equally into Sham (Sham), intestinal I/R (I/R) and intestinal I/R + pravastatin (I/R + PA) groups between 6 and 8 weeks.

1) Sham group (Sham): after 1h of pretreatment by injecting PBS solution into the abdominal cavity, only performing laparotomy, and separating superior mesenteric artery without clamping;

2) intestinal group I/R (I/R): performing intraperitoneal injection of a PBS solution for 1h for pretreatment, and establishing an intestinal I/R model;

3) intestinal group I/R + Pravastatin (I/R + PA): after 2mg/kg of pravastatin is given to the abdominal cavity for 1h of pretreatment, an intestinal I/R model is established.

2.3 results of the experiment

As shown in figure 1, the results in figure 1 show that the time for reperfusion survival of mice after being subjected to pravastatin treatment after 60min of ischemia can be obviously prolonged, and the survival rate of the mice is improved.

Example 2: pravastatin-mediated alleviation of intestinal histopathomorphological injury induced by intestinal ischemia-reperfusion of mice

1 materials of the experiment

1.1 Experimental animals

24 male C57BL/6J mice with the age of 6-8 weeks are selected for experiments, the weight of the mice is 18-22 g, the mice are purchased from the animal center of southern hospital, the breeding place is the SPF animal laboratory department of southern hospital of southern medical university, and the operation related to the animal breeding process is approved by the ethical committee and meets the ethical requirements of animals.

1.2 reagents and instruments

Pravastatin (MedChemExpress, USA); isoflurane (rewarded life science co.); microvascular arterial clamps (gooey biotechnology limited, chengdu north america); sterile silk thread (Ningbo medical suture needle Co., Ltd.); physiological saline (Shijiazhuang four drugs Co., Ltd.); phosphate Buffer Saline (PBS) ph7.4 buffer (Gibco); hematoxylin-eosin staining (beijing rekino bio); absolute ethanol (Guangdong Guanghua science and technology Co., Ltd.); xylene (Guangdong Guanghua science and technology Co., Ltd.); paraffin (lycra); 4% paraformaldehyde (beijing solibao technologies ltd); neutral gums (Solarbio); full-automatic fluorescence microscopy (olympus).

2 experimental methods and results

2.1 animal experiments:

After the blocking and the reperfusion, 0.5ml of warm physiological saline with the temperature of about 37 ℃ is injected subcutaneously for liquid recovery, and after 2 hours of perfusion, intestinal tissues of the mice are taken for detection.

(2) Grouping experiments:

2.2 intestinal histopathological morphological Change detection

Fresh intestinal tissues are placed into 4% paraformaldehyde for soaking and fixing for 24h, then dehydration, embedding and slicing are carried out, hematoxylin-eosin staining is carried out, neutral gum is used for sealing, pathological morphological changes of the intestinal tissues are observed under a full-automatic fluorescence microscope, and then the intestinal mucosa injury is graded and scored by using an improved Chiu method.

2.4 results of the experiment

Results referring to fig. 2, fig. 2A and fig. 2B in fig. 2 are HE staining and scoring results of intestinal tissues showing that the intestinal villi sloughs on the top of the I/R model group, capillaries dilate, and the above lesions of intestinal tissues of mice were significantly improved after administration of pravastatin treatment.

The above data indicate that pravastatin is able to slow down the pathomorphological changes in intestinal tissues of mice that are ischemia-reperfused.

Example 3: pravastatin for inhibiting expression of inflammatory factors in intestinal tissues of mice of intestinal ischemia reperfusion model

1 materials of the experiment

1.1 Experimental animals

1.2 reagents and instruments

Pravastatin (MedChemExpress, USA); isoflurane (rewarded life science co.); microvascular arterial clamps (gooey biotechnology limited, chengdu north america); sterile silk thread (Ningbo medical suture needle Co., Ltd.); physiological saline (Shijiazhuang four drugs Co., Ltd.); phosphate Buffer Saline (PBS) ph7.4 buffer (Gibco); TRIZOL lysate (Invitrogen); chloroform (Guangdong Guanghua); isopropanol (Guangdong Guanghua); absolute ethanol (Guangdong Guanghua); DEPC water (Sigma); SYBR Green fluorescent dye (donyangfang); ReverTra Ace qPCR RT Kit (Toyobo); PCR instrument (Eppendorf, Germany); fluorescent quantitative PCR instrument (applied biosystems AB, USA).

2 experimental methods and results

2.1 animal experiments:

(2) Grouping experiments:

2.2 inflammatory factor mRNA expression

1. The RNA extraction method comprises the following steps:

(1) 20mg to 50mg of intestinal tissue was placed in a 1.5ml RNase-free EP tube, and 500. mu.l of TRIZOL lysate was added thereto and homogenized.

(2) Adding 100 mul chloroform into the homogenate, shaking for 15-20 times, and standing for 1-2 min at room temperature.

(3) Centrifuge at 12,000rpm for 15min at 4 ℃ and pipette the upper aqueous phase into a new RNase-free 1.5ml EP tube.

(4) Adding isopropanol with the same volume, shaking up for 15-20 times, and standing for 10min at room temperature.

(5) Centrifuging at 4 deg.C for 10min at 12,000rpm, discarding the supernatant, adding 1ml 80% ethanol (prepared with DEPC water), shaking, and centrifuging at 4 deg.C for 5min at 7500 rpm.

(6) Discarding the supernatant, centrifuging at 7500rpm at 4 ℃ for 1min, sucking off the residual ethanol, standing at room temperature for 5min to 10min, and adding 50 mul to 100 mul of DEPC water for resuspension. The RNA product was stored in a freezer at-80 ℃ until use.

2. The extracted RNA is subjected to reverse transcription reaction:

(1) mu.l of the extracted RNA was added to 6. mu.l of nucleic-fresh Water and denatured at 65 ℃ for 5min on a PCR amplification machine.

(2) Immediately taking out the mixture from the ice after denaturation, cooling the mixture, adding 2. mu.l of 5 × reaction buffer, 0.5. mu.l of RT Enzyme mix and 0.5. mu.l of Prime mix into the reaction system, and centrifuging the mixture for 3-5 s after slight shaking.

(3) The reaction system was placed on a PCR amplification apparatus, reverse transcription was carried out at 37 ℃ for 15min, and the enzyme was inactivated at 98 ℃ for 5 min.

(4) After the reaction, 190. mu.l of sterile water was added to obtain a cDNA solution.

Real-time PCR reaction:

(1) 6 mul SYBR Green, 1 mul inflammatory factor primer and 5 mul cDNA solution are added into the reaction system and then placed into a fluorescent quantitative PCR instrument.

(2) Real-time PCR reaction conditions: cycling: stage 95 ℃ for 15 s; 1min at 60 ℃ for 40 cycles; melt cure stage: 15s at 95 ℃; 1min at 60 ℃; 30s at 95 ℃; 60 ℃ for 15 s.

2.3 results of the experiment

The results are shown in FIG. 3, and the data in FIG. 3 show that the expression levels of the inflammatory factors IL-beta and IL-6 mRNA in the intestinal tissue of PA group are obviously reduced compared with I/R (p is less than 0.05), and the experimental results show that pravastatin inhibits the expression of the inflammatory factors in the intestinal ischemia-reperfusion intestinal tissue of mice.

The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.

The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.

Claims

1. Application of pravastatin in preparing a medicament for preventing or/and treating intestinal ischemia-reperfusion injury.

2. The use according to claim 1, wherein the medicament comprises pravastatin and pharmaceutically acceptable excipients.

3. Use according to claim 1 or 2, characterized in that said pravastatin comprises 1.5-2.5 mg per 1kg of said medicament.

4. Use according to claim 1 or 2, wherein the medicament is in the form of a tablet.

5. Use according to claim 4, wherein the tablet is a coated tablet.

6. Use according to claim 1 or 2, wherein the medicament is in the form of a capsule.

7. The use according to claim 1 or 2, wherein the medicament is in the form of oral liquid, oral granules or oral powder.

8. Use according to claim 1 or 2, wherein the medicament is in the form of an injection.

9. The use of claim 8, wherein the injection is a lyophilized powder.

10. Use according to claim 8, characterized in that the injection is an emulsion for injection.